FDA Asks Congress For $22 Million In User Fees for Reinspections

The GMP Letter

Device and drug manufacturers may find themselves digging deeper into their pockets to pay proposed FDA user fees to fund the agency’s reinspections of manufacturing plants that fail initial review.

To View This Article:


Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $10.00